Search Results - "Zrazhevskiy, Konstantin"
-
1
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Published in The Lancet (British edition) (11-05-2019)“…Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without…”
Get full text
Journal Article -
2
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Published in The Lancet (British edition) (24-08-2024)“…Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of…”
Get full text
Journal Article -
3
Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients
Published in Journal of thrombosis and haemostasis (01-10-2019)“…Background Parenteral anticoagulants and vitamin K antagonists (VKAs) have constituted the cornerstone of venous thromboembolism (VTE) treatment. Meanwhile,…”
Get full text
Journal Article -
4
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Published in Thrombosis research (01-02-2023)“…Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality…”
Get full text
Journal Article -
5
Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry
Published in Journal of thrombosis and thrombolysis (01-02-2024)“…Although substantial progress has been made in the pathophysiology and management of the post-thrombotic syndrome (PTS), several aspects still need…”
Get full text
Journal Article